Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, we reported prognostic significance of
thromboxane synthase
(
TXAS
) gene expression in invasive bladder cancer. The positive correlation between elevated
TXAS
expression and shorter patient survival supports a potential role for
TXAS
-regulated pathways in tumor metastases. In this study, using immunohistochemical analysis, we found an increased expression of
TXAS
protein in bladder cancer. Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells with the
TXAS
inhibitors furegrelate or ozagrel induced an apoptotic effect measured as an increase in
caspase-3
activation and cell death, and decreased survivin expression. Pharmacological inhibition of
TXAS
using the
TXAS
inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel. Molecular inhibition of
TXAS
expression by siRNA significantly decreased cell growth and migration. In concordance with the pharmacological data, siRNA-mediated reduction of
TXAS
expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells. In summary, the data support a role for the thromboxane A(2) pathway in the pathogenesis of bladder cancer and the potential utility of modulation of this signaling pathway for cancer chemotherapy.
...
PMID:Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. 1760 59
